Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADILNASDAQ:ASLNNASDAQ:ATNFNASDAQ:ENSC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.34-28.7%$0.58$0.22▼$3.00$3.50M1.182.88 million shs14.85 million shsASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AATNF180 Life Sciences$0.83-4.3%$1.01$0.66▼$17.75$5.04M0.23798,622 shs26,480 shsENSCEnsysce Biosciences$2.24+0.9%$2.34$1.62▼$14.67$5.31M0.98949,490 shs34,849 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals0.00%+36.55%-49.23%-47.16%-70.86%ASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%-75.00%ATNF180 Life Sciences0.00%-3.96%-18.63%-19.02%-49.70%ENSCEnsysce Biosciences0.00%+10.89%+2.28%-12.50%-70.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals2.866 of 5 stars3.83.00.00.02.60.01.3ASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATNF180 Life Sciences1.0472 of 5 stars0.05.00.00.02.60.00.6ENSCEnsysce Biosciences0.2988 of 5 stars0.02.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.50Strong Buy$8.002,287.35% UpsideASLNASLAN Pharmaceuticals 0.00N/AN/AN/AATNF180 Life Sciences 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ASLN, ENSC, ADIL, and ATNF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.64 per shareN/AASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09ATNF180 Life SciencesN/AN/AN/AN/A$2.91 per shareN/AENSCEnsysce Biosciences$5.21M1.02N/AN/A$2.59 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.46N/AN/AN/AN/A-218.88%-177.61%8/12/2025 (Estimated)ASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/AATNF180 Life Sciences-$6.17MN/A0.00∞N/AN/A-147.32%-76.99%8/11/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)Latest ASLN, ENSC, ADIL, and ATNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ATNF180 Life SciencesN/A-$0.67N/A-$0.67N/AN/A5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A1.991.99ASLNASLAN PharmaceuticalsN/A1.051.05ATNF180 Life SciencesN/A1.021.02ENSCEnsysce BiosciencesN/A2.502.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%ASLNASLAN Pharmaceuticals58.82%ATNF180 Life Sciences4.07%ENSCEnsysce Biosciences5.63%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%ASLNASLAN Pharmaceuticals4.69%ATNF180 Life Sciences0.17%ENSCEnsysce Biosciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2010.44 million9.99 millionNo DataASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableATNF180 Life Sciences76.07 million6.06 millionNo DataENSCEnsysce Biosciences102.37 million2.18 millionNot OptionableASLN, ENSC, ADIL, and ATNF HeadlinesRecent News About These CompaniesEnsysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2June 24, 2025 | accessnewswire.comAEnsysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025June 11, 2025 | accessnewswire.comAensysce biosciences appoints baker tilly as new auditorJune 7, 2025 | investing.comEnsysce Flat on Receiving GrantJune 4, 2025 | baystreet.caEnsysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose ProtectionJune 4, 2025 | accessnewswire.comAENSC is Moving Closer to Changing the Pain Relief MarketMay 14, 2025 | finance.yahoo.comEnsysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q ResultsMay 14, 2025 | marketwatch.comEnsysce Biosciences Reports First Quarter 2025 Financial ResultsMay 13, 2025 | accessnewswire.comAEnsysce Biosciences Bolsters Management Team with Regulatory ExpertMay 12, 2025 | accessnewswire.comAEnsysce Biosciences secures patent for OUD treatmentApril 25, 2025 | uk.investing.comEnsysce Biosciences receives U.S. patent for OUD treatmentApril 25, 2025 | markets.businessinsider.comEnsysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross ProceedsApril 24, 2025 | accessnewswire.comAEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | gurufocus.comEnsysce Biosciences Stock Doubles In One Trading Session - Here's WhyApril 23, 2025 | benzinga.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | accessnewswire.comAEnsysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use DisorderApril 23, 2025 | accessnewswire.comAEnsysce Biosciences announces data from opioid overdose protection studyApril 17, 2025 | markets.businessinsider.comEnsysce Biosciences files to sell 980,000 shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comENSC Shows Compound Protects Against AbuseApril 15, 2025 | msn.comEnsysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s ThrilledApril 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASLN, ENSC, ADIL, and ATNF Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.34 -0.13 (-28.67%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.31 -0.02 (-7.19%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.ASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 06/27/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.180 Life Sciences NASDAQ:ATNF$0.83 -0.04 (-4.27%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.84 +0.01 (+0.84%) As of 06/27/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Ensysce Biosciences NASDAQ:ENSC$2.24 +0.02 (+0.90%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.16 -0.08 (-3.35%) As of 06/27/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
